Moderna, ta sanar a yau cewa Ma'aikatar Abinci da Kare Magunguna ta Koriya (MFDS) ta ba da izinin tallace-tallace don Spikevax®, rigakafin Moderna's COVID-19 (mRNA-1273) wanda Samsung Biologics ya ƙera, babban CDMO na duniya wanda ke ba da cikakkiyar haɗakar ƙarshen- ci gaban kwangila da sabis na masana'antu.
Wannan izinin tallace-tallacen da Moderna Korea ta samu a hukumance ya ba da damar allurar COVID-19 na Moderna da aka ƙera a wuraren samar da magunguna na gida na Samsung Biologics a rarraba a cikin Koriya kuma a fitar dashi zuwa wasu ƙasashe.
Moderna Korea ta nemi cikakken izinin tallace-tallace don Spikevax® tare da MFDS a farkon Nuwamba kuma ta samu nasarar samun ta cikin lokaci guda.
Philippines da Colombia sun ba da izinin yin amfani da gaggawa na rigakafin Moderna COVID-19 wanda Samsung Biologics ya ƙera a ranar 26 ga Nuwamba da Disamba 2, bi da bi.
"Muna godiya ga Ma'aikatar Abinci da Tsaro ta Koriya don shawarar da suka yanke na amincewa da wannan izinin tallan. Haɗin gwiwarmu da Samsung Biologics don cika-da-kammala masana'antar rigakafin Moderna COVID-19 yana taimaka mana mu ci gaba da haɓaka ƙarfin masana'antarmu a wajen Amurka, "in ji Stéphane Bancel, Babban Jami'in Moderna. "Tare da abokan aikinmu, mun jajirce don kayar da cutar ta COVID-19."
John ya ce "Hakika wannan wani muhimmin ci gaba ne yayin da muka sami damar hanzarta aiwatar da amincewa cikin sauri tare da hadin gwiwa tare da gwamnatin Koriya da Moderna, musamman a karkashin tsauraran matakan MFDS don fara samar da allurar rigakafin mRNA a Koriya," in ji John. Rim, Shugaba na Samsung Biologics. "Mun kuma yi alfaharin nuna kudurinmu na samar da inganci da inganci a duk tsawon ayyukanmu, kuma za mu ci gaba da yin aiki kafada da kafada da abokin cinikinmu don samar da samfuran daidai gwargwado musamman saboda karuwar mahimmanci da bukatar alluran rigakafi a yakin da ake yi da COVID. - 19 annoba."
Moderna yana da abokan hulɗa da yawa na dabaru don masana'anta cika-ƙasa. A cikin Amurka, wannan ya haɗa da Katalent, Inc. (NYSE: CTLT), Abubuwan da aka bayar na Baxter BioPharma Solutions da kuma Sanofi (Nasdaq: SNY). A wajen Amurka, wannan ya haɗa da rovi (BME: ROVI) in Spain, Recipharm a Faransa da kuma Samsung Biologics (KRX: 207940.KS) a Koriya.
Game da Moderna
A cikin shekaru 10 tun farkonsa, Moderna ya canza daga wani kamfani na bincike-binciken kimiyya wanda ke haɓaka shirye-shirye a fagen manzo RNA (mRNA), zuwa wani kamfani mai fa'ida mai fa'ida daban-daban na alluran rigakafi da hanyoyin warkewa a cikin hanyoyin bakwai, babban fayil ɗin mallakar fasaha. a cikin yankunan da suka hada da mRNA da lipid nanoparticle formulation, da kuma haɗin gwiwar masana'anta wanda ke ba da damar samar da asibiti da kasuwanci a sikelin da kuma saurin da ba a taɓa gani ba. Moderna yana kula da ƙawance tare da ɗimbin kewayon gwamnati na cikin gida da na ketare da masu haɗin gwiwar kasuwanci, waɗanda suka ba da izinin bin kimiyyar ƙasa da saurin haɓaka masana'antu. Kwanan nan, damar Moderna sun taru don ba da izinin amfani da ɗayan farkon kuma mafi inganci rigakafin cutar ta COVID-19.
Dandalin mRNA na Moderna yana ginawa akan ci gaba da ci gaba a cikin asali da kuma amfani da kimiyyar mRNA, fasahar bayarwa da masana'antu, kuma ya ba da izinin haɓaka hanyoyin warkewa da rigakafin cututtukan cututtuka, immuno-oncology, cututtukan da ba kasafai ba, cututtukan zuciya da jijiyoyin jini da cututtukan auto-immune. Moderna an nada shi babban ma'aikacin biopharmaceutical ta Science shekaru bakwai da suka gabata. Don ƙarin koyo, ziyarci www.modernatx.com.
Abubuwan da aka bayar na Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) CDMO cikakke ne wanda ke ba da haɓaka kwangilar fasaha na zamani, masana'anta, da sabis na gwajin gwaje-gwaje. Tare da ingantattun amincewar ka'idoji, mafi girman ƙarfin aiki, da mafi saurin kayan aiki, Samsung Biologics abokin zaɓi ne wanda ya sami lambar yabo kuma yana da iko na musamman don tallafawa haɓakawa da kera samfuran halittu a kowane mataki na tsari yayin saduwa da haɓakar buƙatun biopharmaceutical. kamfanoni a duniya. Don ƙarin bayani, ziyarci www.samsungbiologics.com.
